US89532M1018
US89532M1018
Trevi Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.88B EUR | 2.65B EUR | 1.53B EUR | 1.61B EUR |
Enterprise Value | 1.51B EUR | 2.59B EUR | 1.51B EUR | 1.59B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -22.86x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 5.84x | 8.24x | 8.9x | 8.77x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -25.4x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.77% | -2% | -2.96% | -1.78% |